小鼠成纤维细胞生长因子23 ELISA检测试剂盒
产品名称： 小鼠成纤维细胞生长因子23 ELISA检测试剂盒
英文名称： Mouse FGF-23 （C-Term）ELISA Kit
产品编号： CRM-26
产品价格： 0
产品产地： 美国
品牌商标： 0
更新时间： null
使用范围： null
北京科瑞美科技有限公司
- 联系人 :
- 地址 : 北京市海淀区厢黄旗2号楼1层
- 邮编 : 100044
- 所在区域 : 北京
- 电话 : 153****8455
- 传真 : 010-56125083
- 邮箱 : keruimeibio@126.com
骨生化标志物ELISA试剂盒详细介绍：
一.产品名称：
通用名称：小鼠成纤维细胞生长因子23 ELISA检测试剂盒
英文名称：Mouse FGF-23 （C-Term） ELISA Kit
二.Mouse FGF-23 （ C-Term ） ELISA Kit Enzyme-Linked ImmunoSorbent Assay （ELISA）for the Quantitative Determination of Mouse Fibroblast Growth Factor 23 Levels in Serum, Plasma or Cell Culture Media.
三.Mouse FGF-23 （ C-Term ） ELISA Kit INTENDED USE
This kit is intended for research use only in the quantitative determination of Mouse FGF-23 levels in serum, plasma or cell culture media. This assay is also useful in the determination of Rat FGF-23 levels.
四.Mouse FGF-23 （ C-Term ） ELISA Kit INTRODUCTION
Fibroblast growth factor 23 （FGF-23）is a recently discovered, novel member of a large family of related proteins. Its gene encodes a 251 amino acid protein. The amino-terminal portion of FGF-23 （aa 1-24）is hydrophobic and is likely to serve as a signal peptide allowing its secretion into the blood circulation. Its carboxyl-terminal portion （aa 180-251）shares only limited amino acid homology with other members of the FGF family of proteins.
Renal phosphate wasting disorders leading to hypophosphatemia are among the causes of defective mineralization of bone and growth plate development. Autosomal dominant hypophosphatemic rickets （ADHR）, a rare genetic disorder, results from one of several different FGF-23 mutations that make the protein resistant to proteolytic cleavage. Furthermore, tumors that cause oncogenic osteomalacia （OOM）have been shown to overexpress FGF-23 mRNA making it likely that elevated concentrations of FGF-23 in the blood are the cause of renal phosphate wasting. Consistent with this conclusion, the administration of recombinant FGF-23 to rodents was shown to increase urinary excretion of phosphate thus leading to hypophosphatemia and
osteomalacia/rickets. Recent studies with chronic kidney disease （CKD）patients have shown Mouse FGF-23 （ C-Term ） ELISA Kit to be an early predictor of abnormal renal tubular function, bone mineralization, disease progression and over-all mortality risk. Taken together, all currently available data suggest that the measurement of FGF-23 levels may provide an important diagnostic tool for the evaluation of hypophosphatemic and hyperphosphatemic disorders.
一.产品名称：
通用名称：小鼠成纤维细胞生长因子23 ELISA检测试剂盒
英文名称：Mouse FGF-23 （C-Term） ELISA Kit
二.Mouse FGF-23 （ C-Term ） ELISA Kit Enzyme-Linked ImmunoSorbent Assay （ELISA）for the Quantitative Determination of Mouse Fibroblast Growth Factor 23 Levels in Serum, Plasma or Cell Culture Media.
三.Mouse FGF-23 （ C-Term ） ELISA Kit INTENDED USE
This kit is intended for research use only in the quantitative determination of Mouse FGF-23 levels in serum, plasma or cell culture media. This assay is also useful in the determination of Rat FGF-23 levels.
四.Mouse FGF-23 （ C-Term ） ELISA Kit INTRODUCTION
Fibroblast growth factor 23 （FGF-23）is a recently discovered, novel member of a large family of related proteins. Its gene encodes a 251 amino acid protein. The amino-terminal portion of FGF-23 （aa 1-24）is hydrophobic and is likely to serve as a signal peptide allowing its secretion into the blood circulation. Its carboxyl-terminal portion （aa 180-251）shares only limited amino acid homology with other members of the FGF family of proteins.
Renal phosphate wasting disorders leading to hypophosphatemia are among the causes of defective mineralization of bone and growth plate development. Autosomal dominant hypophosphatemic rickets （ADHR）, a rare genetic disorder, results from one of several different FGF-23 mutations that make the protein resistant to proteolytic cleavage. Furthermore, tumors that cause oncogenic osteomalacia （OOM）have been shown to overexpress FGF-23 mRNA making it likely that elevated concentrations of FGF-23 in the blood are the cause of renal phosphate wasting. Consistent with this conclusion, the administration of recombinant FGF-23 to rodents was shown to increase urinary excretion of phosphate thus leading to hypophosphatemia and
osteomalacia/rickets. Recent studies with chronic kidney disease （CKD）patients have shown Mouse FGF-23 （ C-Term ） ELISA Kit to be an early predictor of abnormal renal tubular function, bone mineralization, disease progression and over-all mortality risk. Taken together, all currently available data suggest that the measurement of FGF-23 levels may provide an important diagnostic tool for the evaluation of hypophosphatemic and hyperphosphatemic disorders.